Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval

Merck & Co., Inc.’s PD-1 inhibitor Keytruda has won US approval for use in combination with Seagen Inc. ’s antibody-drug conjugate (ADC) Padcev for the treatment of first-line urothelial carcinoma in an industry first, but analysts have some concerns about the regimen’s tolerability.

The US Food and Drug Administration approved Keytruda (pembrolizumab) with the nectin-4-directed antibody and microtubule inhibitor ADC Padcev (enfortumab vedotin) for first-line locally advanced or metastatic urothelial carcinoma patients ineligible...